CYTOMEL Drug Patent Profile
✉ Email this page to a colleague
When do Cytomel patents expire, and what generic alternatives are available?
Cytomel is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in CYTOMEL is liothyronine sodium. There are four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cytomel
A generic version of CYTOMEL was approved as liothyronine sodium by XGEN PHARMS on August 17th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYTOMEL?
- What are the global sales for CYTOMEL?
- What is Average Wholesale Price for CYTOMEL?
Summary for CYTOMEL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 12 |
Patent Applications: | 1,189 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CYTOMEL |
Drug Sales Revenues: | Drug sales revenues for CYTOMEL |
What excipients (inactive ingredients) are in CYTOMEL? | CYTOMEL excipients list |
DailyMed Link: | CYTOMEL at DailyMed |
![CYTOMEL drug patent expirations Drug patent expirations by year for CYTOMEL](/p/graph/s/t/CYTOMEL-patent-expirations.png)
![Drug Prices for CYTOMEL](/p/graph/drug-price/CYTOMEL.png)
![Drug Sales Revenue Trends for CYTOMEL](/p/graph/drug-sales-revenues/CYTOMEL.png)
Recent Clinical Trials for CYTOMEL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Virginia Commonwealth University | Phase 2 |
Oregon Health and Science University | Phase 1 |
Johns Hopkins University | Phase 1 |
Pharmacology for CYTOMEL
Drug Class | l-Triiodothyronine |
US Patents and Regulatory Information for CYTOMEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |